LCM
ABEO icon

Legato Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Legato Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
16,830
+3,650
+28% +$20K 0.01% 659
2026
Q1 		$59K Hold
13,180
– – 0.01% 710
2025
Q4 		$69.5K Buy
13,180
+2,290
+21% +$11.5K 0.01% 732
2025
Q3 		$57.5K Buy
+10,890
New +$69.1K 0.01% 545

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Legato Capital Management's ABEO Position: Q2 2026 in Review

Legato Capital Management increased its Abeona Therapeutics (ABEO) stake by 28% in Q2 2026, buying an estimated $20K and bringing the position to 16,830 shares worth $104K. The position accounts for 0.01% of the portfolio, ranked #659.

Legato Capital Management first reported a position in ABEO in Q3 2025 and has held it in 4 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Legato Capital Management held 16,830 shares of Abeona Therapeutics worth $104K as of Q2 2026.
  • Legato Capital Management bought 3,650 Abeona Therapeutics shares in Q2 2026, an estimated $20K.
  • Abeona Therapeutics made up 0.01% of Legato Capital Management's portfolio in Q2 2026, its #659 holding.
  • Legato Capital Management first reported a position in Abeona Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.